An Indian Patent titled “Novel Formulation containing native or recombinant Apotransferrin or Lactoferrin nanoparticle loaded with biological alone or in combination with chemotherapeutic agents for targeted delivery” has been granted to Prof. Anand Kondapi, Department of Biotechnology and Bioinformatics at University of Hyderabad (UoH). The patent was applied on 19 June 2017, which was granted on 20 July 2023.
Dr. Kondapi and his team consisting of Dr. Sonali Khanra (work related to siRNA delivery for treatment of glioma); Dr. S. L. Balakrishna (work related to use of recombinant apotranferrin in delivery of SiRNA); Dr. Jagadesh Senapathi (work related to development of regulated delivery system); Dr. Chukhu Muj (work related p53 DNA based treatment for prostate cancer); Ms. Neha Tomar (currently working on DNA delivery system) and Ms. Antham Soni (currently working on combination therapy using biological and chemotherapeutic agents for cancer) are involved in the research work.
In the current treatment of cancer and other disease conditions, there is a requirement of use of a biological alone (DNA, siRNA, Antibody) or in combination of biological with a chemotherapeutic agent. During chemotherapy, the biological (DNA, RNA, Antibody) are given separately and drugs are given separately, it is not certain whether both will reach the intended cell like cancer or disease bearing cells. Thus, encapsulating biological and drug together in a nanoparticle will facilitate the delivery of the drug and biological together facilitating action of both of them in the target cell. Another important feature of the technology is the use of natural proteins, the protein present in the cow milk, Lactoferrin or the protein present in the blood, Apo transferrin as a nano vehicle. The receptors for these two proteins are highly expressed in metabolically active cancer cells, thus when administered orally or intravenous route these nanoparticles reach cancer cells, delivering the cargo of biological and/or drug(s) conferring intended effect for degeneration of cancer.
This patent provides a targeted delivery formulation that can deliver biological alone or a combination of biological with chemotherapeutic drug or Biological with a regulated/delayed delivery of chemotherapeutic agent based on the disease requirement. If this technology is realized in a clinical set-up, there will be wide applications and advantages in treatment of cancer, gene therapy, and other related conditions.
Indian Patent No. 439803
Application no. 201741017576 Date of filing: 19/06/2017 Date of grant: 20/07/2023